Match tier
Likely match
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-08-08
K
Khiem Phan
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Graduate Student Researcher
1 pubs
Research Areas
Biography and Research Information
OverviewAI-generated summary
Khiem Phan's research focuses on meta-analyses of clinical trials. Their recent work includes a meta-analysis of randomized trials comparing oral selective estrogen receptor degrader monotherapy with standard endocrine therapy for estrogen receptor-positive, HER2-negative advanced breast cancer with ESR1 mutations. This publication contributes to understanding treatment efficacy in specific breast cancer subtypes.
Metrics
- Publications: 1
Selected Publications
-
Oral selective estrogen receptor degrader monotherapy versus standard endocrine therapy in estrogen receptor-positive, HER2-negative advanced breast cancer with ESR1 mutations: A meta-analysis of randomized trials. (2026)
Collaboration Network
Top Collaborators
Zainab Sabir
Jacobi Medical Center (US)
1 shared publication
- Oral selective estrogen receptor degrader monotherapy versus standard endocrine therapy in estrogen receptor-positive, HER2-negative advanced breast cancer with ESR1 mutations: A meta-analysis of randomized trials.
Mirza Muhammad Hadeed Khawar
Services Institute of Medical Sciences (PK)
1 shared publication
- Oral selective estrogen receptor degrader monotherapy versus standard endocrine therapy in estrogen receptor-positive, HER2-negative advanced breast cancer with ESR1 mutations: A meta-analysis of randomized trials.
Sarjana Singh
Government Medical College and Hospital (IN)
1 shared publication
- Oral selective estrogen receptor degrader monotherapy versus standard endocrine therapy in estrogen receptor-positive, HER2-negative advanced breast cancer with ESR1 mutations: A meta-analysis of randomized trials.
Asmaa Abu Obaid
Abu Dhabi University (AE)
1 shared publication
- Oral selective estrogen receptor degrader monotherapy versus standard endocrine therapy in estrogen receptor-positive, HER2-negative advanced breast cancer with ESR1 mutations: A meta-analysis of randomized trials.
Jungwook Heo
Yuhan University (KR)
1 shared publication
- Oral selective estrogen receptor degrader monotherapy versus standard endocrine therapy in estrogen receptor-positive, HER2-negative advanced breast cancer with ESR1 mutations: A meta-analysis of randomized trials.
Shinjit Mani
Chittaranjan National Cancer Institute (IN)
1 shared publication
- Oral selective estrogen receptor degrader monotherapy versus standard endocrine therapy in estrogen receptor-positive, HER2-negative advanced breast cancer with ESR1 mutations: A meta-analysis of randomized trials.
Srinidhi Prabusankar
Jawaharlal Nehru Medical College (IN)
1 shared publication
- Oral selective estrogen receptor degrader monotherapy versus standard endocrine therapy in estrogen receptor-positive, HER2-negative advanced breast cancer with ESR1 mutations: A meta-analysis of randomized trials.
Sai Shyamala Vaishnavi Erambalur
Dominica State College (DM)
1 shared publication
- Oral selective estrogen receptor degrader monotherapy versus standard endocrine therapy in estrogen receptor-positive, HER2-negative advanced breast cancer with ESR1 mutations: A meta-analysis of randomized trials.
Sailesh Mandal
Chittaranjan National Cancer Institute (IN)
1 shared publication
- Oral selective estrogen receptor degrader monotherapy versus standard endocrine therapy in estrogen receptor-positive, HER2-negative advanced breast cancer with ESR1 mutations: A meta-analysis of randomized trials.
Sejun Seo
Hanyang University (KR)
1 shared publication
- Oral selective estrogen receptor degrader monotherapy versus standard endocrine therapy in estrogen receptor-positive, HER2-negative advanced breast cancer with ESR1 mutations: A meta-analysis of randomized trials.
Mahmud Seyi Abdurrahman
St. Vincent and the Grenadines Community College (VC)
1 shared publication
- Oral selective estrogen receptor degrader monotherapy versus standard endocrine therapy in estrogen receptor-positive, HER2-negative advanced breast cancer with ESR1 mutations: A meta-analysis of randomized trials.
Muneeb Khawar
Services Institute of Medical Sciences (PK)
1 shared publication
- Oral selective estrogen receptor degrader monotherapy versus standard endocrine therapy in estrogen receptor-positive, HER2-negative advanced breast cancer with ESR1 mutations: A meta-analysis of randomized trials.
Similar Researchers
Based on overlapping research topics
Sonya Utecht
University of Arkansas for Medical Sciences
Meta-analysis and systematic reviews
Cancer Treatment and Pharmacology
Breast Cancer Treatment Studies
A.A. Khalil
University of Arkansas at Fayetteville
Meta-analysis and systematic reviews
Cancer Treatment and Pharmacology
Breast Cancer Treatment Studies
Alan Baltz
University of Arkansas for Medical Sciences
Meta-analysis and systematic reviews
Cancer Treatment and Pharmacology
Breast Cancer Treatment Studies
Nishanth Thalambedu
University of Arkansas for Medical Sciences
Meta-analysis and systematic reviews
Cancer Treatment and Pharmacology
Receptor Mechanisms and Signaling
Rui Zhang
University of Arkansas for Medical Sciences
Meta-analysis and systematic reviews
Cancer Treatment and Pharmacology
Bryan E. White
University of Arkansas at Little Rock
Cancer Treatment and Pharmacology
Breast Cancer Treatment Studies